Hyperdynamic left ventricular ejection fraction is associated with higher mortality in COVID-19 patients.
Am Heart J Plus
; 14: 100134, 2022 Feb.
Article
in English
| MEDLINE | ID: covidwho-1859249
ABSTRACT
Study objective:
To compare the characteristics and outcomes of COVID-19 patients with a hyperdynamic LVEF (HDLVEF) to those with a normal or reduced LVEF.Design:
Retrospective study.Setting:
Rush University Medical Center.Participants:
Of the 1682 adult patients hospitalized with COVID-19, 419 had a transthoracic echocardiogram (TTE) during admission and met study inclusion criteria.Interventions:
Participants were divided into reduced (LVEF < 50%), normal (≥50% and <70%), and hyperdynamic (≥70%) LVEF groups. Main outcomemeasures:
LVEF was assessed as a predictor of 60-day mortality. Logistic regression was used to adjust for age and BMI.Results:
There was no difference in 60-day mortality between patients in the reduced LVEF and normal LVEF groups (adjusted odds ratio [aOR] 0.87, p = 0.68). However, patients with an HDLVEF were more likely to die by 60 days compared to patients in the normal LVEF group (aOR 2.63 [CI 1.36-5.05]; p < 0.01). The HDLVEF group was also at higher risk for 60-day mortality than the reduced LVEF group (aOR 3.34 [CI 1.39-8.42]; p < 0.01).Conclusion:
The presence of hyperdynamic LVEF during a COVID-19 hospitalization was associated with an increased risk of 60-day mortality, the requirement for mechanical ventilation, vasopressors, and intensive care unit.
COVID-19; COVID-19, coronavirus disease 2019; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; Heart failure; Hyperdynamic; ICU, intensive care unit; LVEF, left ventricular ejection fraction; Left ventricular ejection fraction; MACE, major adverse cardiovascular events; NLVEF, normal left ventricular ejection fraction; RLVEF, reduced left ventricular ejection fraction; SARS-CoV-2; TTE, transthoracic echocardiogram
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Language:
English
Journal:
Am Heart J Plus
Year:
2022
Document Type:
Article
Affiliation country:
J.ahjo.2022.100134
Similar
MEDLINE
...
LILACS
LIS